Teva Pharmaceutical Industries (NYSE:TEVA) has seen its stock move steadily over the past month, gaining about 5%. Investors ...

Department of Health and Human Services will hold a public conference on Wednesday to outline plans for accelerating the ...

Food and Drug Administration on Wednesday said it is aiming to reduce the number of human clinical studies required for ...

TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- . (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in ...

Harel Insurance Investments & Financial Services Ltd. increased its Teva holding to 6.84% of its reportable U.S. equity ...

Teva Pharmaceuticals has agreed to pay $35 million and withdraw six patents from a U.S. regulatory list to settle claims that the drugmaker delayed generic competition for its QVAR asthma inhalers, ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?

Teva Pharmaceutical Industries Ltd. will pay $35 million to settle claims it delayed generic competition in the asthma inhaler market.

Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes ...

Teva Pharmaceuticals has recalled multiple lots of prazosin hydrochloride after detecting nitrosamine above FDA-approved ...